Diabetes Drugs and Heart Risk
New Studies Link Avandia, but Not Actos, to Heart Attacks
Study: Actos Has Heart Attack-Stroke Benefit, Not Risk continued...
"While this is by no means definitive -- we don't absolutely know the two drugs are different -- there is increasing evidence the two agents produce different effects regarding [heart attack and stroke] complications. If one is thinking about taking one of these drugs, one should take this into account," Solomon tells WebMD.
GSK takes issue with the Lincoff study. The company notes that much of the data comes from a study funded by Actos maker Takeda Pharmaceuticals.
"No clinical head-to-head trial data specifically evaluates cardiovascular risk between Avandia and Actos; however, the head-to-head data that does exist, and the overwhelming majority of comparative observational data, show no significant differences in cardiovascular events," the GSK statement says. "Analyzed studies show no difference in the [heart attack and stroke] effects of Avandia versus other oral antidiabetic medicines, including Actos."
Lincoff says the new analysis offers new information on Actos.
"The previous study showed the reduction in heart attacks in a high-risk group of patients," he says. "This now includes patients at lower risk, without established risk of heart disease, and we saw the same results. There is the same benefit in all subgroups. All of the data points in the same direction. It is much more reassuring that these results are indicative of the real outcomes in patients."
Robert Spanheimer, MD, Takeda's senior medical director for diabetes, agrees that the Lincoff study strengthens the conclusions of the Takeda-funded study of Actos's heart-related effects.
"This information, combined with the [earlier] study, should give patients the confidence that Actos does not increase heart attack-related events or mortality," Spanheimer tells WebMD.
Actos, Avandia: New Drug Class, New Side Effects
Actos and Avandia are the two available members of a class of drugs called thiazolidinediones, TZDs, or PPAR agonists. They're also called glitazones, after the suffix used in the drugs' generic names.
The drugs activate an important chemical-signaling pathway that controls some of the body's most basic functions. That pathway has several signal boxes, called PPAR receptors. Nobody yet knows all of the things that happen when drugs activate PPAR receptors. But two things happen that are good for people with diabetes: The cells of the body become more sensitive to insulin, and blood sugar levels go down.